Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Earendil Labs Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct art unit and 1 distinct examiner. This reflects a very specific and limited current engagement with the USPTO. The lack of additional pending matters suggests a highly targeted patent strategy.
MARCSISIN, ELLEN JEAN is the busiest examiner, with 1 pending action. As the sole examiner for the portfolio, her review will determine the outcome of the 1 pending office action. There are no other examiners or art units involved to provide alternative perspectives or comparative data within this technology area.
For practitioners, the entire prosecution strategy is centered on the 1 distinct examiner and the 1 distinct art unit. The 1 pending office action in Biotechnology & Pharmaceuticals requires a targeted response that addresses the specific concerns of MARCSISIN, ELLEN JEAN. Without additional pending matters, the company's current USPTO experience is entirely defined by this single interaction, making the quality of the response critical.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARCSISIN, ELLEN JEAN | 1 | 34.6% | +49.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19312682 | ANTIBODY AND USE THEREOF | MARCSISIN, ELLEN JEAN | — |
| Art Unit | Apps |
|---|---|
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19312682 | ANTIBODY AND USE THEREOF | MARCSISIN, ELLEN JEAN | 1677 | §112Other | Non-Final OA | — | Pending | Aug 28, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEarendil Labs Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ellen Jean Marcsisin has the most, with 1 of Earendil Labs Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
